Enteral High-dose DHA Supplementation on Bronchopulmonary Dysplasia in Very Preterm Infants: a Collaborative Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,801

Participants

Timeline

Start Date

July 30, 2023

Primary Completion Date

November 15, 2023

Study Completion Date

March 31, 2026

Conditions
Bronchopulmonary DysplasiaChild DevelopmentNeonatal and Perinatal Conditions
Interventions
DIETARY_SUPPLEMENT

High-dose DHA

Direct enteral DHA supplementation at a dose of at least 40 mg/kg/day or DHA supplementation of breast milk or formula aiming for at least 0.4% of total fatty acids.

DIETARY_SUPPLEMENT

Control

Control with no or low-dose DHA.

Trial Locations (1)

G1V 4G2

CHU de Québec-Université Laval, Québec

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Laval University

OTHER

collaborator

South Australian Health and Medical Research Institute

OTHER

collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

lead

CHU de Quebec-Universite Laval

OTHER